Janux Therapeutics (JANX) Invested Capital (2020 - 2025)
Historic Invested Capital for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $976.6 million.
- Janux Therapeutics' Invested Capital rose 4884.15% to $976.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $976.6 million, marking a year-over-year increase of 4884.15%. This contributed to the annual value of $1.0 billion for FY2024, which is 19701.87% up from last year.
- Latest data reveals that Janux Therapeutics reported Invested Capital of $976.6 million as of Q3 2025, which was up 4884.15% from $990.5 million recorded in Q2 2025.
- Over the past 5 years, Janux Therapeutics' Invested Capital peaked at $1.0 billion during Q4 2024, and registered a low of $299.5 million during Q2 2023.
- In the last 5 years, Janux Therapeutics' Invested Capital had a median value of $371.5 million in 2021 and averaged $542.0 million.
- Per our database at Business Quant, Janux Therapeutics' Invested Capital surged by 260257.55% in 2021 and then tumbled by 1289.8% in 2023.
- Janux Therapeutics' Invested Capital (Quarter) stood at $366.3 million in 2021, then dropped by 12.44% to $320.7 million in 2022, then increased by 7.36% to $344.3 million in 2023, then soared by 197.02% to $1.0 billion in 2024, then dropped by 4.52% to $976.6 million in 2025.
- Its Invested Capital was $976.6 million in Q3 2025, compared to $990.5 million in Q2 2025 and $1.0 billion in Q1 2025.